952152-79-3

Basic information

• Product Name: (S)-N-((3-(3,5-difluoro-4-(2-bromo-10-oxo-5,6,8,9-tetrahydro-10H-4,4b,7,9a-tetraazabenzo[a]azulen-7-yl)phenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide
• Synonyms: (S)-N-((3-(3,5-difluoro-4-(2-bromo-10-oxo-5,6,8,9-tetrahydro-10H-4,4b,7,9a-tetraazabenzo[a]azulen-7-yl)phenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide
• CAS NO: 952152-79-3
• Molecular Weight: 551.347
• Mol File: 952152-79-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (S)-N-((3-(3,5-difluoro-4-(2-bromo-10-oxo-5,6,8,9-tetrahydro-10H-4,4b,7,9a-tetraazabenzo[a]azulen-7-yl)phenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-N-((3-(3,5-difluoro-4-(2-bromo-10-oxo-5,6,8,9-tetrahydro-10H-4,4b,7,9a-tetraazabenzo[a]azulen-7-yl)phenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide(952152-79-3)
• EPA Substance Registry System: (S)-N-((3-(3,5-difluoro-4-(2-bromo-10-oxo-5,6,8,9-tetrahydro-10H-4,4b,7,9a-tetraazabenzo[a]azulen-7-yl)phenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide(952152-79-3)

Safety Data

• Hazardous Substances Data: 952152-79-3(Hazardous Substances Data)

Upstream product

• 952150-42-4 5(S)-(acetylaminomethyl)-3-(3,5-difluoro-4-(1-(tertbutoxycarbonyl)[1,2,5]triazepan-5-yl)phenyl)oxazolidin-2-one 
• 78686-86-9 5-bromo-2-chloro-pyridine-3-carbonyl chloride 

Relevant articles and documents

Synthesis and in vitro/in vivo antibacterial activity of oxazolidinones having thiocarbamate at C-5 on the A-ring and an amide- or urea-substituted [1,2,5]triazepane or [1,2,5]oxadiazepane as the C-ring

Oxazolidinones bearing a seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane heterocycle substituted with an amide or urea functionality as the C-ring and having a [1,2,3]triazole, a thiocarbamate, an isoxazole-3-ylamino, or a thioacetamide C-5 side chain unit on the A-ring instead of the typical acetamide were synthesized and their in vitro antibacterial activities towards various pathogens were evaluated. Several derivatives exhibited potent in vitro antibacterial activity toward not only Gram-positive, but also Gram-negative and linezolid-resistant pathogens. The in vivo therapeutic effects of amide 11a and ureas 16e, 17a were 2- to 3-fold greater than that of linezolid in a systemic mouse infection model treated by intravenous administration. Furthermore, compounds 11a and 17a showed lower monoamine oxidase (MAO)-inhibitory activity than our previously reported potent oxazolidinone antibacterials 3a and 3b.